Clinical Trial Details
| Trial ID: | L0144 |
| Source ID: | NCT04006145 |
| Associated Drug: | Elobixibat |
| Title: | A Phase 2 Study of Elobixibat in Adults With NAFLD or NASH |
| Acronym: | -- |
| Status: | Completed |
| Study Results: | Has Results |
| Results: | https://ClinicalTrials.gov/show/NCT04006145/results |
| Conditions: | NAFLD|NASH |
| Interventions: | Drug: Elobixibat|Drug: Placebo oral tablet |
| Outcome Measures: | Change From Baseline in Serum Low Density Lipoprotein-cholesterol (LDL-C) at Week 16 |
| Sponsor/Collaborators: | Albireo |
| Gender: | All |
| Age: | 18 Years and older ?? (Adult, Older Adult) |
| Phases: | Phase 2 |
| Enrollment: | 47 |
| Study Type: | Interventional |
| Study Designs: | Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment |
| Start Date: | June 6, 2019 |
| Completion Date: | July 15, 2020 |
| Results First Posted: | September 27, 2021 |
| Last Update Posted: | September 27, 2021 |
| Locations: | Hope Clinical Research, Canoga Park, California, United States|Inland Empire Clinical Trials, LLC, Rialto, California, United States|Peak Gastroenterology Associates, Colorado Springs, Colorado, United States|Integrity Clinical Research, LLC, Doral, Florida, United States|Nature Coast Clinical Research, Inverness, Florida, United States|Guardian Angel Research Center, Inc., Tampa, Florida, United States|Mercy Medical Center, Baltimore, Maryland, United States|American Research Corporation at the Texas Liver Institute, San Antonio, Texas, United States|Virginia Commonwealth University, Richmond, Virginia, United States|University of Washington, Seattle, Washington, United States |
| URL: | https://ClinicalTrials.gov/show/NCT04006145 |
